This site is for customers in Asia. Customers in China & other regions, please go to Global page.
HOME > Product search results > Code No. D060-3 Anti-RCAS1 (Human) mAb

Code No. D060-3

Anti-RCAS1 (Human) mAb

Availability (in Japan)

1-9

(In Japan at 00:05,
Apr 17, 2024 in JST)

Size

100 µL (1 mg/mL)

Data
  • Immunohistochemistry

Clonality Monoclonal Clone 22-1-1
Isotype (Immunized Animal) Mouse IgM
Applications
FCM
1-5 µg/mL (final concentration)  
IC
1-5 µg/mL  
IH*
reported.  (PMID: 15904507 / 17849467 / 24167369
Immunogen (Antigen) Human uterine cervical adenocarcinoma cells
Reactivity [Gene ID]

Human[9166]

Storage buffer 1 mg/mL in PBS/50% glycerol, pH 7.2
Storage temp. -20°C Conjugate Unlabeled Manufacturer MBL
Alternative names EBAG9, EB9, PDAF
Background RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. The predicted amino acid sequence of RCAS1 (213 aa) possesses an N-terminal transmembrane region and a coiled-coil structure in the C-terminal portion, indicating that RCAS1 is a type II membrane protein able to form oligomers through the coiled-coil structure. RCAS1 revealed different expression pattern from the known tumor associated antigens such as, YH206, GA733, CA125, CEA and sialyl Lewis molecules in human tumor cell lines. Recent study indicated RCAS1 acts as a ligand for a putative receptor present on various human cells including T, B and NK cells. RCAS1 inhibited the in vitro growth of receptor-expressing cells and induced apoptosis. It was suggested that tumor cells might evade immune surveillance by expression of RCAS1.
Related products D060-3H Anti-RCAS1 (Human) mAb
M079-3 Mouse IgM (isotype control)
Citations

Flow Cytometry

  1. Wolf J et al. Role of EBAG9 protein in coat protein complex I-dependent glycoprotein maturation and secretion processes in tumor cells. FASEB J. 24, 4000-19 (2010)(PMID:20570965)

Immunohistochemistry

  1. Reimer TA et al. Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker. BMC Cancer. 5, 47 (2005)(PMID:15904507)
  2. Theocharis S et al. RCAS1 expression in mobile tongue squamous cell carcinoma: an immunohistochemical study. Med Sci Monit. 17, BR228-234 (2011)(PMID:17849467)
  3. Giaginis C et al. Increased RCAS1 expression is associated with advanced histopathological stage and poor prognosis in patients with gastric adenocarcinoma. Dis Markers. 35, 213-9 (2013)(PMID:24167369)
  4. Giaginis C et al. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) expression in human benign and malignant thyroid lesions. Med Sci Monit. 18, BR123-9 (2012)(PMID:22460085)
  5. Leelawat K et al. Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer. J Clin Pathol. 56, 764-8 (2003)(PMID:14514780)
  6. Oshikiri T et al. Tumor-associated antigen recognized by the 22-1-1 monoclonal antibody encourages colorectal cancer progression under the scanty CD8+ T cells. Clin Cancer Res 12, 411-6 (2006)(PMID:16428480)
Product category
Research area
Cancer
Apoptosis
この製品に関するお問い合わせをする

  • The availability is based on the information in Japan at 00:05, Apr 17, 2024 in JST.
  • The special price is shown in red color.
  • Please note that products cannot be ordered from this website. To purchase the items listed in this website, please contact us or local distributers.
  • Abbreviations for applications:
    WB: Western Blotting, IH: Immunohistochemistry, IC: Immunocytochemistry, IP: Immunoprecipitation
    FCM: Flow Cytometry, NT: Neutralization, IF: Immunofluorescence, RIP: RNP Immunoprecipitation
    ChIP: Chromatin Immunoprecipitation, CoIP: Co-Immunoprecipitation
  • For applications and reactivity:
    *: The use is reported in a research article (Not tested by MBL). Please check the data sheet for detailed information.
    **: The use is reported from the licenser (Under evaluation or not tested by MBL).
  • For storage temparature: RT: room temparature
  • Please note that products in this website might be changed or discontinued without notification in advance for quality improvement.